Replies to post #170 on Enterologics Inc. (fka ELGO)

[stockforyou1]

The other ELGO alert that I received.

New Trade Suggestion

Enterologics Inc (OTCBB: ELGO)

• Alert Price: 0.48
• Sell Point: when you are comfortable with the gains

Recent Developments

Monday, ELGO released news that it is in process of acquiring or licensing specific probiotic strains and developing these to meet the exacting standards necessary for FDA approval as prescription biologics for specific gastrointestinal (GI) indications.

Many GI disorders are poorly addressed by current therapies, including pouchitis, irritable bowel syndrome (IBS), Crohn's disease, ulcerative colitis and Clostridium difficile infections.

Today, most probiotic bacteria are sold over-the-counter as dietary supplements or in food products such as yogurt, with ambiguous benefits. Instead, ELGO plans to commercialize its probiotic strains as biologics, each meeting FDA standards for clinical efficacy and approval for a specific indication.

"ELGO believes that this will establish a unique and strong competitive position in the market."
-Bob Hoerr, Co-Founder and President.

Enterologics will bring specific probiotic strains to market as FDA-approved biologic drugs, using:

• A rigorous testing program to prove clinical efficacy for inadequately treated GI disease
• A new preservation technology that to maintain viable bacterial cells and long shelf-life

Fresh interest in probiotics was prompted by reports in the popular press linking yogurt consumption with longevity. There were also grave concerns in the medical literature about a striking rise in antibiotic resistant bacteria as well as the destructive effects of antibiotics on the healthy gut flora. More recently, the presence of damaging bacteria residing in the gut (H. pylori) has been shown to be a primary cause of peptic ulcers, a disease that had previously been thought to be caused by too much acid or stress.

Some scientists believe that infection with a yet-to-be microorganism may be an underlying factor leading to inflammatory bowel disease. These trends stimulated more research on strains of bacteria isolated from healthy gut flora as well as from the family of strains used to ferment foods and dairy products, resulting in the identification of a number of Lactobacillus, bifidobacteria, E. coli and yeast strains that had beneficial effects on human and animal health.

Stay tuned for further updates regarding ELGO.

For more information on ELGO, please visit http://www.enterologics. com/index.html

[moneymaker168]

Checking out ELGO, Website: http://www.enterologics.com/company.html

Who we are:
Enterologics is a publicly traded company (ELGO.OB). We were founded in 2009 for the sole purpose of making probiotics available as new therapeutic alternatives for inadequately treated GI diseases. We operate as a virtual team of experts and partner with the best outside biologic production resources we can identify. Our goal is to keep development costs low and make time to market as fast as possible.

Our mission is to bring unique strains of probiotic bacteria to market as FDA-approved “live biotherapeutics” for gastrointestinal diseases.

Our guiding principles:
Minimize development risk. Probiotic strains we acquire will have prior human use and evidence of safety and therapeutic benefits. We will build a strong scientific portfolio by extensive strain characterization, including state-of-the-art genomic profiling.

Enhance value by following a rigorous product development template. We develop our probiotic strains as “live biotherapeutics” following FDA guidelines to demonstrate the safety and clinical efficacy of biologic drugs. This builds the scientific underpinnings needed to ensure the highest quality product and unequivocal demonstration of clinical benefit.

Engineer quality and product performance. Selection of the optimal dosage form is important as the right probiotic. We have identified a superior formulation technology called “vitrification” that extends shelf live better than traditional freeze-drying. This new preservation technology, coupled with rigorous production and quality standards, will ensure prescriber confidence that our products deliver viable bacteria at a reproducible and effective dose.